Innovative Oral Treatment Mimics Gastric Bypass to Combat Obesity

A groundbreaking human study introduces SYNT-101, an investigational once-daily oral medication showing promising results in addressing obesity by replicating the metabolic effects of gastric bypass surgery. The research, presented at the European Congress on Obesity in Malaga, Spain, involved nine healthy participants who received various doses of SYNT-101 and underwent safety and efficacy assessments.

The treatment works by forming a temporary polydopamine coating in the duodenum, the first section of the small intestine. This coating redirects nutrients to the lower intestine, mimicking the nutrient absorption changes seen after gastric bypass surgery. This mechanism promotes satiety, aids in glycemic control, and supports metabolic balance while potentially preserving lean muscle mass better than other weight-loss medications like GLP-1 receptor agonists.

Participants tolerated the medication well, with no adverse events or significant gastrointestinal side effects reported. Endoscopic imaging confirmed the polymer coating safely formed and was naturally eliminated within 24 hours. Blood tests indicated favorable hormonal changes, including increased leptin and decreased ghrelin levels, which are associated with reduced appetite.

Although the trial was not designed to measure weight loss, preliminary data showed delayed glucose absorption, suggesting effective nutrient redirection. Larger studies are planned, with the company preparing to submit an Investigational New Drug application to the FDA later this year to advance development.

Overall, SYNT-101 offers a novel, convenient, and potentially more sustainable approach to obesity management by harnessing the body’s own metabolic pathways, with further research needed to confirm its long-term safety and efficacy.